The Business Times
SUBSCRIBERS

Valeant goes on defensive against investor critics

It is publicly revealing for the first time the benefits that it gets from some price increases; says it has not been as dependent on drug price increases as analysts' reports claim

Published Wed, Oct 7, 2015 · 09:50 PM
Share this article.

San Francisco

AMID an intensifying debate over drug price increases that has brought its business practices to the forefront, Valeant Pharmaceuticals International Inc fired back at critics in the investment community, publicly revealing the benefits that it gets from some price hikes for the first time.

Democrats in the US House of Representatives are pushing to subpoena the company for documents relating to drug price i…

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

Consumer & Healthcare

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here